Research Topics
Genomes and Genes | G DranoffSummaryAffiliation: Harvard University Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Enhancing the clinical activity of granulocyte-macrophage colony-stimulating factor-secreting tumor cell vaccinesMasahisa Jinushi
Department of Medical Oncology and Cancer Vaccine Center, Dana Farber Cancer Institute, Boston, MA, USA
Immunol Rev 222:287-98. 2008..Together, these results define key regulatory circuits that attenuate immune-mediated tumor destruction and suggest novel combinatorial therapies that might enhance the clinical activity of GM-CSF-secreting tumor cell vaccines...- Tailor-made renal cell carcinoma vaccinesGlenn Dranoff
Department of Medical Oncology and Cancer Vaccine Center, Dana Farber Cancer Institute, Boston, MA 02215, USA
Cancer Cell 22:287-9. 2012..A new study of peptide vaccines in advanced renal cell carcinoma patients provides important insights into these central issues... 
Defining the critical hurdles in cancer immunotherapyBernard A Fox
Earle A, Chiles Research Institute, Robert W, Franz Research Center, Providence Cancer Center, Providence Portland Medical Center, Portland, OR, USA
J Transl Med 9:214. 2011..Each of these hurdles can significantly delay clinical translation of promising advances in immunotherapy yet if overcome, have the potential to improve outcomes of patients with cancer...
GM-CSF-secreting melanoma vaccinesGlenn Dranoff
Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
Oncogene 22:3188-92. 2003....- GM-CSF-based cancer vaccinesGlenn Dranoff
Department of Adult Oncology, Dana Farber Cancer Institute and Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
Immunol Rev 188:147-54. 2002..The formulation of simplified methods for manufacturing autologous, GM-CSF-secreting tumor cells has enabled more extensive clinical testing in diverse patient settings... - Cytokines in cancer pathogenesis and cancer therapyGlenn Dranoff
Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
Nat Rev Cancer 4:11-22. 2004 - Targets of protective tumor immunityGlenn Dranoff
Department of Medical Oncology and Cancer Vaccine Center, Dana Farber Cancer Institute, Boston, MA 02115, USA
Ann N Y Acad Sci 1174:74-80. 2009..Our findings suggest that components of the NKG2D pathway may be attractive targets for therapeutic monoclonal antibodies... - Coordinated tumor immunityGlenn Dranoff
Department of Medical Oncology, Dana-Farber Cancer Institute, Dana 510E, 44 Binney Street, Boston, MA 02115, USA
J Clin Invest 111:1116-8. 2003 - Cancer gene therapy: connecting basic research with clinical inquiryG Dranoff
Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
J Clin Oncol 16:2548-56. 1998.... - Experimental mouse tumour models: what can be learnt about human cancer immunology?Glenn Dranoff
Department of Medical Oncology and the Cancer Vaccine Center, Dana Farber Cancer Institute, and Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02215, USA
Nat Rev Immunol 12:61-6. 2012..To accelerate the translation of these findings into clinical benefits, investigators need to gain a better understanding of the strengths and limitations of mouse model systems as tools for deciphering human antitumour immune responses... - Interleukin 3 and granulocyte-macrophage colony-stimulating factor are not required for induction of chronic myeloid leukemia-like myeloproliferative disease in mice by BCR/ABLS Li
The Center for Blood Research, Dana-Farber Cancer Institute, and Harvard Institutes of Medicine and Howard Hughes Medical Institute, Harvard Medical School, Boston, MA, USA
Blood 97:1442-50. 2001..These results demonstrate that IL-3 and GM-CSF are not required for BCR/ABL-induced CML-like leukemia in mice and suggest that autocrine production of IL-3 does not play a role in established chronic phase CML in humans... - CML66, a broadly immunogenic tumor antigen, elicits a humoral immune response associated with remission of chronic myelogenous leukemiaX F Yang
Center for Hematologic Oncology, Dana Farber Cancer Institute, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
Proc Natl Acad Sci U S A 98:7492-7. 2001..These findings suggest that CML66 may be immunogenic in a wide variety of malignancies and may be a target for antigen-specific immunotherapy... - Overlapping roles for granulocyte-macrophage colony-stimulating factor and interleukin-3 in eosinophil homeostasis and contact hypersensitivityS Gillessen
Department of Adult Oncology, Dana Farber Cancer Institute Harvard Medical School, Boston, MA, USA
Blood 97:922-8. 2001..Together, these findings delineate overlapping roles for GM-CSF and IL-3 in hematopoiesis and immunity. (Blood. 2001;97:922-928).. - Gene immunotherapy in murine acute myeloid leukemia: granulocyte-macrophage colony-stimulating factor tumor cell vaccines elicit more potent antitumor immunity compared with B7 family and other cytokine vaccinesK Dunussi-Joannopoulos
Dana Farber Cancer Institute and Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
Blood 91:222-30. 1998..1-AML vaccines. These preclinical data emphasize that GM-CSF gene immunotherapy deserves clinical evaluation in AML... - CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapyJ L Schultze
Department of Adult Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
J Clin Invest 100:2757-65. 1997..We, therefore, contend that CD40-activated B cells are an alternative source of highly efficient APCs with which to generate antigen-specific T cells ex vivo for autologous adoptive immunotherapy... - Interpreting cancer vaccine clinical trialsG Dranoff
Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA, USA
J Gene Med 1:80-3. 1999.... - Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patientsF Stephen Hodi
Department of Adult Oncology, Dana-Farber Cancer Institute and Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA
Proc Natl Acad Sci U S A 100:4712-7. 2003..These findings suggest that CTLA-4 antibody blockade increases tumor immunity in some previously vaccinated cancer patients... - Induction of myeloproliferative disease in mice by tyrosine kinase fusion oncogenes does not require granulocyte-macrophage colony-stimulating factor or interleukin-3M H Tomasson
Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
Blood 97:1435-41. 2001.... - Targeting melanoma inhibitor of apoptosis protein with cancer immunotherapyJ C Schmollinger
Department of Medical Oncology, Dana-Farber Cancer Institute and Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA
Apoptosis 9:309-13. 2004..These findings demonstrate that ML-IAP can serve as a tumor rejection antigen, although additional vaccine targets will be required to circumvent immune escape and tumor heterogeneity... - CD1d-restricted T cells regulate dendritic cell function and antitumor immunity in a granulocyte-macrophage colony-stimulating factor-dependent fashionSilke Gillessen
Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
Proc Natl Acad Sci U S A 100:8874-9. 2003..DCs from immunized CD1d-deficient mice showed compromised maturation and function. Together, these results delineate a role for CD1d-restricted T cell-DC cross talk in the shaping of antitumor immunity... - MFG-E8-mediated uptake of apoptotic cells by APCs links the pro- and antiinflammatory activities of GM-CSFMasahisa Jinushi
Department of Medical Oncology and Cancer Vaccine Center, Dana Farber Cancer Institute, Boston, MA 02115, USA
J Clin Invest 117:1902-13. 2007..These findings clarify the immunoregulatory effects of apoptotic cells and suggest new therapeutic strategies to modulate CD4(+) T cell subsets in cancer and autoimmunity... - Melanoma inhibitor of apoptosis protein (ML-IAP) is a target for immune-mediated tumor destructionJan C Schmollinger
Department of Adult Oncology, Dana-Farber Cancer Institute and Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA
Proc Natl Acad Sci U S A 100:3398-403. 2003..These findings demonstrate that ML-IAP can serve as a target for immune-mediated tumor destruction, but that antigen-loss variants can accomplish immune escape... - Immune therapy for cancerMichael Dougan
Department of Medical Oncology and Cancer Vaccine Center, Dana Farber Cancer Institute and Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
Annu Rev Immunol 27:83-117. 2009..The future of immune therapy for cancer is likely to combine many of these approaches to generate more effective treatments... - Therapy-induced antibodies to MHC class I chain-related protein A antagonize immune suppression and stimulate antitumor cytotoxicityMasahisa Jinushi
Department of Medical Oncology and Cancer Vaccine Center, Dana-Farber Cancer Institute and Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA
Proc Natl Acad Sci U S A 103:9190-5. 2006..Moreover, these results highlight the therapeutic potential of anti-MICA antibodies to overcome immune suppression and effectuate tumor destruction in patients... - Alpha-CTLA-4 mAb-associated panenteritis: a histologic and immunohistochemical analysisDarryl A Oble
Department of Pathology, Massachusetts General Hospital, Boston, MA 02114 2696, USA
Am J Surg Pathol 32:1130-7. 2008.... - Cathepsin S required for normal MHC class II peptide loading and germinal center developmentG P Shi
Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
Immunity 10:197-206. 1999..These results indicate cathepsin S is a major Ii-processing enzyme in splenocytes and dendritic cells. Its role in humoral immunity critically depends on how antigens access the immune system... - The biologic importance of tumor-infiltrating lymphocytesF Stephen Hodi
Department of Medical Oncology and Cancer Vaccine Center, Dana Farber Cancer Institute, Boston, MA, USA
J Cutan Pathol 37:48-53. 2010..These findings show a concordance between the immune signature of tumor protection in endogenous and therapy-induced responses, strongly supporting Martin Mihm's original insights... - Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patientsF Stephen Hodi
Department of Medical Oncology and Cancer Vaccine Center, Dana Farber Cancer Institute, Brigham and Women s Hospital and Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA
Proc Natl Acad Sci U S A 105:3005-10. 2008.... - Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotypeShuji Ogino
Center for Molecular Oncologic Pathology, Dana Farber Cancer Institute, Brigham and Women s Hospital, Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA
Clin Cancer Res 15:6412-20. 2009.... - CML28 is a broadly immunogenic antigen, which is overexpressed in tumor cellsXiao Feng Yang
Center for Hematologic Oncology, Dana Farber Cancer Institute, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
Cancer Res 62:5517-22. 2002..Moreover, given its expression and immunogenicity in a wide variety of malignancies, CML28 merits additional evaluation as a target for antigen-specific immunotherapy... - Protein disulfide isomerases are antibody targets during immune-mediated tumor destructionCatia Fonseca
Department of Medical Oncology and Cancer Vaccine Center, Dana Farber Cancer Institute, Boston, MA 02115, USA
Blood 113:1681-8. 2009..Together, these findings reveal the unexpected immunogenicity of PDIs and raise the possibility that these gene products might serve as targets for therapeutic monoclonal antibodies... - Functional deficiencies of granulocyte-macrophage colony stimulating factor and interleukin-3 contribute to insulitis and destruction of beta cellsThomas Enzler
Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
Blood 110:954-61. 2007..These results, together with previous reports of impaired hematopoietic responses to GM-CSF and IL-3 in patients with T1D and in NOD mice, indicate that functional deficiencies of these cytokines contribute to diabetes... - MUC1-like tandem repeat proteins are broadly immunogenic in cancer patientsJoseph A Mollick
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA
Cancer Immun 3:3. 2003..These data add to the growing list of tumor antigens that appear to be translated in two frames, and suggest that OGFr and OGFr-ARF may be useful targets for vaccination... - Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanomaRobert Soiffer
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
J Clin Oncol 21:3343-50. 2003..CONCLUSION: Vaccination with irradiated, autologous melanoma cells engineered to secrete GM-CSF by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma... - Detection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemiaC J Wu
Center for Hematologic Oncology, and Department of Biostatistical Science, Dana Farber Cancer Institute, and Department of Medicine, and Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
J Clin Invest 106:705-14. 2000..The characterization of B cell-defined antigens may help identify clinically relevant targets of the GVL response in vivo... - Dual roles for immunity in gastrointestinal cancersCristina Ferrone
Dana Farber Cancer Institute, 44 Binney St, Dana 520C, Boston, MA 02115, USA
J Clin Oncol 28:4045-51. 2010..Here, we discuss the dual roles of immunity in cancer development, focusing on gastrointestinal malignancies, given the depth of recent insights into the mechanisms underlying these tumors... - ATP6S1 elicits potent humoral responses associated with immune-mediated tumor destructionF Stephen Hodi
Department of Adult Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
Proc Natl Acad Sci U S A 99:6919-24. 2002..Taken together, these findings demonstrate that potent humoral responses to ATP6S1 are associated with immune-mediated destruction of diverse tumors... - The immune response to tumorsMichael Dougan
Department of Medical Oncology and Cancer Vaccine Center, Dana Farber Cancer Institute and Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts, USA
Curr Protoc Immunol . 2009..Through a deeper understanding of the complicated relationship between tumors and the immune system, tumor immunology strives to harness the immune system to generate protective antitumor responses in patients... - CD1d and CD1d-restricted iNKT-cells play a pivotal role in contact hypersensitivityEdward E S Nieuwenhuis
Gastrointestinal Division, Brigham and Women s Hospital, Boston, MA, USA
Exp Dermatol 14:250-8. 2005..Thus, pharmacologic antagonists of CD1d can be used as effective inhibitors of CHS, a prototype for a variety of delayed-type tissue hypersensitivity responses... - Capitalizing on the immunogenicity of dying tumor cellsCatia Fonseca
Department of Medical Oncology, Dana Farber Cancer Institute, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
Clin Cancer Res 14:1603-8. 2008.... - TIM-1 and TIM-4 glycoproteins bind phosphatidylserine and mediate uptake of apoptotic cellsNorimoto Kobayashi
Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney Street, Harvard Medical School, Boston, MA 02115, USA
Immunity 27:927-40. 2007..These results show that TIM-4 and TIM-1 are immunologically restricted members of the group of receptors whose recognition of PS is critical for the efficient clearance of apoptotic cells and prevention of autoimmunity... - Role for interleukin-3 in mast-cell and basophil development and in immunity to parasitesC S Lantz
Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215, USA
Nature 392:90-3. 1998..These findings establish a role for IL-3 in immunity to parasites and indicate that one of the functions of IL-3 in host defence against infection is to expand populations of haematopoietic effector cells... - Milk fat globule EGF-8 promotes melanoma progression through coordinated Akt and twist signaling in the tumor microenvironmentMasahisa Jinushi
Department of Medical Oncology and Cancer Vaccine Center, Dana Farber Cancer Institute, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
Cancer Res 68:8889-98. 2008..Together, these findings delineate pleiotropic roles for MFG-E8 in the tumor microenvironment and raise the possibility that systemic MFG-E8 blockade might prove therapeutic for melanoma patients... - Overlapping synthetic peptides encoding TPD52 as breast cancer vaccine in mice: prolonged survivalSaied Mirshahidi
Department of Cancer Immunology and AIDS, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, United States
Vaccine 27:1825-33. 2009..We show that an OSP vaccination approach can assist in the disruption of self-tolerance and conclude that our approach may hold promise for immunoprevention of early-stage cancers in a general population... 
Deficiencies of GM-CSF and interferon gamma link inflammation and cancerThomas Enzler
Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
J Exp Med 197:1213-9. 2003..These findings demonstrate that the interplay of infectious agents with cytokine-mediated regulation of immune homeostasis is a critical determinant of cancer susceptibility...- The therapeutic implications of intratumoral regulatory T cellsGlenn Dranoff
Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
Clin Cancer Res 11:8226-9. 2005 - In vivo evidence for the role of GM-CSF as a mediator in acute pancreatitis-associated lung injuryJean Louis Frossard
Department of Surgery, Beth Israel Hospital Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02115, USA
Am J Physiol Lung Cell Mol Physiol 283:L541-8. 2002..Our findings indicate that GM-CSF plays a critical role in coupling pancreatitis to ALI and suggest that GM-CSF may act indirectly by regulating the release of other proinflammatory factors including MIP-2... - Complete response to donor lymphocyte infusion in multiple myeloma is associated with antibody responses to highly expressed antigensRoberto Bellucci
Dana-Farber Cancer Institute, M530, 44 Binney St, Boston, MA 02115, USA
Blood 103:656-63. 2004..The expression of these genes was evaluated in primary myeloma cells and in normal plasma cells. This study demonstrates that the GVM response is associated with antibody responses to highly expressed myeloma-associated antigens... - Inciting inflammation: the RAGE about tumor promotionMichael Dougan
Department of Medical Oncology and Cancer Vaccine Center, Dana Farber Cancer Institute, Boston, MA 02115, USA
J Exp Med 205:267-70. 2008..New data show that feed-forward signals downstream of the receptor for advanced glycation end-products (RAGE) can fuel chronic inflammation, creating a microenvironment that is ideal for tumor formation... - MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myelomaMasahisa Jinushi
Department of Medical Oncology and Cancer Vaccine Center, Dana Farber Cancer Institute, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
Proc Natl Acad Sci U S A 105:1285-90. 2008..Together, these findings reveal that the alterations in the NKG2D pathway are associated with the progression from MGUS to MM and raise the possibility that anti-MICA monoclonal antibodies might prove therapeutic for these disorders... - Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinomaRavi Salgia
Department of Adult Oncology, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02215, USA
J Clin Oncol 21:624-30. 2003..One mixed response was observed. CONCLUSION: Vaccination with irradiated autologous NSCLC cells engineered to secrete GM-CSF enhances antitumor immunity in some patients with metastatic NSCLC... - Involvement of interleukin-3 in delayed-type hypersensitivityN Mach
Department of Medicine, Dana Farber Cancer Institute, Boston, MA 02115, USA
Blood 91:778-83. 1998..These findings reveal a critical role for IL-3 in some forms of delayed-type hypersensitivity... - Triggering tumor immunity through angiogenesis targetingMasahisa Jinushi
Department of Medical Oncology and Cancer Vaccine Center, Dana-Farber Cancer Institutel, Boston, Massachusetts 02115, USA
Clin Cancer Res 13:3762-4. 2007 - Biologic activity of irradiated, autologous, GM-CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantationVincent T Ho
Department of Medical Oncology and Cancer Vaccine Center, Dana Farber Cancer Institute, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
Proc Natl Acad Sci U S A 106:15825-30. 2009.... - Modeling genomic diversity and tumor dependency in malignant melanomaWilliam M Lin
Department of Medical Oncology, Center for Cancer Genome Discovery, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
Cancer Res 68:664-73. 2008..Genetically defined cell culture collections therefore offer a rich framework for systematic functional studies in melanoma and other tumors... - High-throughput oncogene mutation profiling in human cancerRoman K Thomas
Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston, Massachusetts 02115, USA
Nat Genet 39:347-51. 2007..These results offer a new dimension in tumor genetics, where mutations involving multiple cancer genes may be interrogated simultaneously and in 'real time' to guide cancer classification and rational therapeutic intervention... - Concerted potent humoral immune responses to autoantigens are associated with tumor destruction and favorable clinical outcomes without autoimmunityTaylor Sittler
University of Massachusetts Medical School, Worcester, Massachusetts, USA
Clin Cancer Res 14:3896-905. 2008..We sought to identify targets of responses from this vaccination strategy... - CTLA-4 blockade: unveiling immune regulationGlenn Dranoff
J Clin Oncol 23:662-4. 2005 - Erythropoietin receptor haploinsufficiency and in vivo interplay with granulocyte-macrophage colony-stimulating factor and interleukin 3Armin G Jegalian
Department of Molecular and Medical Pharmacology, Molecular Biology Institute, University of California Los Angeles School of Medicine, Los Angeles, CA 90095 1735, USA
Blood 99:2603-5. 2002..These results suggest EpoR haploinsufficiency and promotion of in vivo erythropoiesis by GM-CSF and IL-3... - Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant gliomaPeter E Fecci
Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
Cancer Res 66:3294-302. 2006..These findings dramatically alter our understanding of depressed cellular immune function in patients with malignant glioma and advance a role for T(regs) in facilitating tumor immune evasion in the central nervous system... - Granulocyte/macrophage colony-stimulating factor and accessory cells modulate radioprotection by purified hematopoietic cellsTamiko R Katsumoto
Department of Pediatrics, University of California, San Francisco, CA 94143, USA
J Exp Med 201:853-8. 2005..These data demonstrate a nonredundant function of GM-CSF in radioprotection by donor hematopoietic cells that may prove relevant in clinical transplantation... - IL-7 induces myelopoiesis and erythropoiesisFrancesca B Aiello
Laboratory of Molecular Immunoregulation, National Cancer Institute, Frederick, MD 21702, USA
J Immunol 178:1553-63. 2007..This study demonstrates that IL-7 can promote nonlymphoid hemopoiesis and production of cytokines active in the host defense system in vivo, supporting its possible clinical utility... - Donor leukocyte infusion from immunized donors increases tumor vaccine efficacy after allogeneic bone marrow transplantationTakanori Teshima
Department of Internal Medicine, University of Michigan Cancer Center, 1500 East Medical Center Drive, Ann Arbor, MI 48109-0942, USA
Cancer Res 62:796-800. 2002..This strategy has important implications to prevent recurrence of malignancies after BMT...
Research Grants
- Targeting MFG-E8 as Melanoma ImmunotherapyGlenn Dranoff; Fiscal Year: 2010..Work in this project will clarify the ways in which MFG-E8 blockade accomplishes melanoma killing, which in turn should support the development of MFG-E8 targeted treatments for melanoma patients. ..
- Targets of Immune-Mediated Tumor DestructionGlenn Dranoff; Fiscal Year: 2009..Determine whether vaccination with the murine homologs of these antigens can stimulate protective immunity against challenge with murine melanoma cells. ..
- Targets of Immune-Mediated Tumor DestructionGlenn Dranoff; Fiscal Year: 2007..Determine whether vaccination with the murine homologs of these antigens can stimulate protective immunity against challenge with murine melanoma cells. ..
- CSF DEFICIENCY AND ANTITUMOR IMMUNITYGlenn Dranoff; Fiscal Year: 2004..3). To develop strategies for reconstituting tumor defense in mice deficient in GM-CSF, IL-3, and IFN-gamma. ..
- CSF DEFICIENCY AND ANTITUMOR IMMUNITYGlenn Dranoff; Fiscal Year: 2001..2. To evaluate the ability of GM-CSF and IL-3 deficient mice to process exogenous antigens for MHC class I presentation. 3. To evaluate the functions of GM-CSF and IL-3 in promising cancer vaccination strategies. ..
- Targeting MFG-E8 as Melanoma ImmunotherapyGlenn Dranoff; Fiscal Year: 2011..Work in this project will clarify the ways in which MFG-E8 blockade accomplishes melanoma killing, which in turn should support the development of MFG-E8 targeted treatments for melanoma patients. ..